Under priority review status, China’s National Medical Products Administration has approved BeiGene’s (NASDAQ:BGNE)
Brukinsa (zanubrutinib) for the treatment of adults with chronic
lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) who have
received at least one prior therapy and adults with mantle cell lymphoma
(MCL) who have received at least one prior therapy.
The FDA OK’d the BTK inhibitor in November 2019 for MCL.
https://seekingalpha.com/news/3579967-beigenes-zanubrutinib-okd-in-china-for-blood-cancers
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.